title: [Hypotensive effect of three different formulations of brimonidine tartrate in normal eyes].
abstract: OBJECTIVE
  To compare the hypotensive effect in normal eyes of three formulations with different concentrations of brimonidine tartrate: 0.2%; 0.15% and 0.1%.
  
  
  METHODS
  Prospective, randomized, double-blind study included 60 volunteers, who underwent initial ophthalmologic examination and measurement of intraocular pressure (IOP). Individuals were divided into three groups: (1) brimonidine tartrate 0.15%, (2) brimonidine tartrate 0.2% and (3) brimonidine tartrate 0.1% and randomly received one drop each of drops in each eye. The IOP was measured after 30 minutes, 1 hour and 2 hours.
  
  
  RESULTS
  We found that all concentrations of brimonidine tartrate significantly reduced intraocular pressure during the study period, with p<0.05. When analyzing the percentage difference of the hypotensive effect of each group, we found no significant difference between the studied groups: (1) -13.50%, (2) -11.50%, (3) -11.90% after 30 minutes (p=0.650); (1) -24.30%, (2) -18.60%, (3) -18.30% after 1 hour (p=0.324); (1) -29.14%, (2) -21.20%, (3) -25.60% after 2 hours (p=0.068).
  
  
  CONCLUSIONS
  There is no statistically significant difference in intraocular pressure reduction (peak period) between the three formulations of brimonidine.
authors.affiliation: Setor de Córnea e Cirurgia Refrativa, Hospital Oftalmológico de Sorocaba/Banco de Olhos de Sorocaba, Sorocaba (SP), Brazil. tulioabud@yahoo.com
authors.forename: Tulio Batista
authors.initials: TB
authors.lastname: Abud
authors.forename: Marcio
authors.initials: M
authors.lastname: Scuoteguazza Filho
authors.forename: Edjane Souza Santos
authors.initials: ES
authors.lastname: Oliveira
authors.forename: Jorge Felipe
authors.initials: JF
authors.lastname: Abud
authors.forename: João Antonio
authors.initials: JA
authors.lastname: Prata Junior
mesh_terms: D000293:Adolescent; D058647:Adrenergic alpha-2 Receptor Agonists / Q000008:administration & dosage / Q000009:adverse effects; D000328:Adult; D000959:Antihypertensive Agents / Q000008:administration & dosage* / Q000009:adverse effects; D000068438:Brimonidine Tartrate; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects*; D008297:Male; D008875:Middle Aged; D009798:Ocular Hypertension / Q000517:prevention & control*; D011446:Prospective Studies; D011810:Quinoxalines / Q000008:administration & dosage* / Q000009:adverse effects; D013997:Time Factors; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D058647:Adrenergic alpha-2 Receptor Agonists; D000959:Antihypertensive Agents; D011810:Quinoxalines; D000068438:Brimonidine Tartrate